FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Cassava Sciences, Inc. Reports No Evidence of Data Manipulation in 2012 Article”
Cassava Sciences, Inc. (NASDAQ: SAVA) surged over 21% in premarket trading after the company was informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012.
The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company’s lead drug candidate for the proposed treatment of Alzheimer’s disease.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.
For more information, please visit: Cassava Sciences, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.